Long-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration

Journal of Clinical Medicine

Volumn 4, Issue 7, 2015, Pages 1380-1402

  Mrejen, Sarah ^a,b,c   Jung, Jesse J ^a,b,d,e   Chen, Christine ^f,g   Patel, Samir N ^h   Gallego Pinazo, Roberto ⁱ   Yannuzzi, Nicolas ^h   Xu, Luna ^j   Marsiglia, Marcela ^a,b,e   Boddu, Sucharita ^d   Freund, K Bailey ^a,b,d  

^a VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^b EAR AND THROAT HOSPITAL   (United States)

^c CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e New York Presbyterian Hospital   (United States)

^f MONASH UNIVERSITY   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j NEW YORK EYE AND EAR INFIRMARY   (United States)

more..

Author keywords

Anatomical classification; Choroidal neovascularization; Fluorescein angiography classification; Intravitreal anti VEGF injections; Neovascular age related macular degeneration; Treat and Extend Regimen

Indexed keywords

ACETYLSALICYLIC ACID; AFLIBERCEPT; BEVACIZUMAB; CLOPIDOGREL; RANIBIZUMAB; VASCULOTROPIN ANTIBODY; WARFARIN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; BIVARIATE ANALYSIS; COHORT ANALYSIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FUNDUS CAMERA; HUMAN; HYPERTENSION; IMAGE ANALYSIS; INTRAOCULAR PRESSURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; NEOVASCULARIZATION (PATHOLOGY); OPTICAL COHERENCE TOMOGRAPHY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VISUAL ACUITY CHART;

EID: 84966696669     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4071380     Document Type: Article

References (41)

1. Friedman, D.S.; O’Colmain, B.J.; Munoz, B.; Tomany, S.C.; McCarty, C.; de Jong, P.T.; Nemesure, B.; Mitchell, P.; Kempen, J. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 2004, 122, 564–572.
2. Ferris, F.L., 3rd; Fine, S.L.; Hyman, L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol. 1984, 102, 1640–1642.
3. Rosenfeld, P.J.; Brown, D.M.; Heier, J.S.; Boyer, D.S.; Kaiser, P.K.; Chung, C.Y.; Kim, R.Y.; Group M.S.; Ranibizumab for neovascular age-related macular degeneration. N. Engl. J.Med. 2006, 355, 1419–1431.
4. Brown, D.M.; Michels, M.; Kaiser, P.K.; Heier, J.S.; Sy, J.P.; Ianchulev, T.; Group A.S.; Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009, 116, 57–65.
5. Brown, D.M.; Regillo, C.D. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: Applying clinical trial results to the treatment of everyday patients. Am. J. Ophthalmol. 2007, 144, 627–637.
6. Cohen, S.Y.; Dubois, L.; Tadayoni, R.; Fajnkuchen, F.; Nghiem-Buffet, S.; Delahaye-Mazza, C.; Guiberteau, B.; Quentel, G. Results of one-year’s treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am. J. Ophthalmol. 2009, 148, 409–413.
7. Engelbert, M.; Zweifel, S.A.; Freund, K.B. “Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 2009, 29, 1424–1431.
8. Freund, K.B.; Korobelnik, J.F.; Devenyi, R.; Framme, C.; Galic, J.; Herbert, E.; Hoerauf, H.; Lanzetta, P.; Michels, S.; Mitchell, P.; et al. Treat-and-extend regimens with anti-VEGF inhibitors in retinal diseases: A consensus. Retina 2014, Submitted.
9. Comparison of Age-related Macular Degeneration Treatments Trials Research Group; Martin, D.F.; Maguire, M.G.; Fine, S.L.; Ying, G.S.; Jaffe, G.J.; Grunwald, J.E.; Toth, C.; Redford, M.; Ferris, F.L., 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012, 119, 1388–1398.
10. Lalwani, G.A.; Rosenfeld, P.J.; Fung, A.E.; Dubovy, S.R.; Michels, S.; Feuer, W.; Davis, J.L.; Flynn, H.W., Jr.; Esquiabro, M. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study. Am. J. Ophthalmol. 2009, 148, 43–58.
11. Fung, A.T.; Kumar, N.; Vance, S.K.; Slakter, J.S.; Klancnik, J.M.; Spaide, R.S.; Freund, K.B. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye (Lond) 2012, 26, 1181–1187.
12. Toalster, N.; Russell, M.; Ng, P. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina 2013, 33, 1351–1358.
13. Abedi, F.; Wickremasinghe, S.; Islam, A.F.; Inglis, K.M.; Guymer, R.H. Anti-VEGF treatment in neovascular age-related macular degeneration: A Treat-and-Extend Protocol Over 2 Years. Retina 2014, 34, 1531–1538.
14. Gupta, O.P.; Shienbaum, G.; Patel, A.H.; Fecarotta, C.; Kaiser, R.S.; Regillo, C.D. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010, 117, 2134–2140.
15. Shienbaum, G.; Gupta, O.P.; Fecarotta, C.; Patel, A.H.; Kaiser, R.S.; Regillo, C.D. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: Clinical and economic impact. Am. J. Ophthalmol. 2012, 153, 468–473.
16. Engelbert, M.; Zweifel, S.A.; Freund, K.B. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified “treat and extend” dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina 2010, 30, 1368–1375.
17. Rayess, N.; Houston, S.K., 3rd; Gupta, O.P.; Ho, A.C.; Regillo, C.D. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am. J. Ophthalmol. 2015, 159, 3–8.
18. Calvo, P.; Wang, Y.; Ferreras, A.; Lam, W.C.; Denevyl, R.; Brent, M.H. Treat and extend versus treat and observe in wet age-related macular degeneration patients treated with ranibizumab: 3-year surveillance period. J. Clin. Exp. Ophthalmol. 2014, 5, 1–5.
19. Oubraham, H.; Cohen, S.Y.; Samimi, S.; Marotte, D.; Bouzaher, I.; Bonicel, P.; Fajnkuchen, F.; Tadayoni, R. Inject and extend dosing versus dosing as needed: A comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011, 31, 26–30.
20. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch. Ophthalmol. 1991, 109, 1220–1231.
21. Grossniklaus, H.E.; Gass, J.D. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am. J. Ophthalmol. 1998, 126, 59–69.
22. Freund, K.B.; Zweifel, S.A.; Engelbert, M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 2010, 30, 1333–1349.
23. Jung, J.J.; Chen, C.Y.; Mrejen, S.; Gallego-Pinazo, R.; Xu, L.; Marsiglia, M.; Boddu, S.; Freund, K.B. The Incidence of Neovascular Subtypes in Newly Diagnosed Neovascular Age-Related Macular Degeneration. Am. J. Ophthalmol. 2014, 158, 769–779.
24. Xu, L.; Mrejen, S.; Jung, J.J.; Gallego-Pinazo, R.; Thompson, D.; Marsiglia, M.; Freund, K.B. Geographic Atrophy in Patients Receiving Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration. Retina 2014, 35, 176–186.
25. Yannuzzi, L.A.; Negrao, S.; Iida, T.; Carvalho, C.; Rodriguez-Coleman, H.; Slakter, J.; Freund, K.B.; Sorenson, J.; Orlock, D.; Borodoker, N. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001, 21, 416–434.
26. Rofagha, S.; Bhisitkul, R.B.; Boyer, D.S.; Sadda, S.R.; Zhang, K.; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology 2013, 120, 2292–2299.
27. Singer, M.A.; Awh, C.C.; Sadda, S.; Freeman, W.R.; Antoszyk, A.N.; Wong, P.; Tuomi, L. HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012, 119, 1175–1183.
28. Rasmussen, A.; Bloch, S.B.; Fuchs, J.; Hansen, L.H.; Larsen, M.; Lacour, M.; Lund-Andersen, H.; Sander, B. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 2013, 120, 2630–2636.
29. Silva, R.; Axer-Siegel, R.; Eldem, B.; Guymer, R.; Kirchhof, B.; Papp, A.; Seres, A.; Gekkieva, M.; Nieweg, A.; Pilz, S.; et al. The SECURE study: Long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology 2013, 120, 130–139.
30. Marcus, D.M. Long-Term Follow-up of Intravitreal Injection for Neovascular Age-Related Macular Degeneration in an Open-Label Extension of the VIEW 1 Study. Abstract presented at: the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; 4–8 May, 2014; Orlando, FL, USA.
31. Shah, V.P.; Freund, K.B. Growth of type 1 neovascularization following cessation of anti-vascular endothelial growth factor therapy as a possible explanation for treatment resistance. JAMA Ophthalmol. 2013, 131, 967–969.
32. Grunwald, J.E.; Daniel, E.; Huang, J.; Ying, G.S.; Maguire, M.G.; Toth, C.A.; Jaffe, G.J.; Fine, S.L.; Blodi, B.; Klein, M.L.; et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014, 121, 150–161.
33. McBain, V.A.; Kumari, R.; Townend, J.; Lois, N. Geographic atrophy in retinal angiomatous proliferation. Retina 2011, 31, 1043–1052.
34. Marsiglia, M.; Boddu, S.; Chen, C.Y.; Jung, J.J.; Mrejen, S.; Gallego-Pinazo, R.; Freund, K.B. Correlation between neovascular lesion type and the clinical characteristics of non-neovascular fellow eyes in patients with unilateral neovascular age-related macular degeneration. Retina 2015, 35, 966–974.
35. Daniel, E.; Toth, C.A.; Grunwald, J.E.; Jaffe, G.J.; Martin, D.F.; Fine, S.L.; Huang, J.; Ying, G.S.; Hagstrom, S.A.; Winter, K.; et al. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014, 121, 656–666.
36. Green, W.R. Histopathology of age-related macular degeneration. Mol. Vis. 1999, 5, 27.
37. Grossniklaus, H.E.; Green, W.R. Choroidal neovascularization. Am. J. Ophthalmol. 2004, 137, 496–503.
38. Bhavsar, K.V.; Freund, K.B. Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid. Saudi J. Ophthalmol. 2014, 28, 129–133.
39. Cohen, S.Y.; Creuzot-Garcher, C.; Darmon, J.; Desmettre, T.; Korobelnik, J.F.; Levrat, F.; Quentel, G.; Palies, S.; Sanchez, A.; de Gendre, A.S.; et al. Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. Br. J. Ophthalmol. 2007, 91, 1173–1176.
40. Hoang, Q.V.; Tsuang, A.J.; Gelman, R.; Mendonca, L.S.; Della Torre, K.E.; Jung, J.J.; Freund, K.B. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina 2013, 33, 179–187.
41. Hoang, Q.V.; Mendonca, L.S.; Della Torre, K.E.; Jung, J.J.; Tsuang, A.J.; Freund, K.B. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012, 119, 321–326.